Učitavanje...

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia

Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ther Adv Hematol
Glavni autori: Gordon, Max J., Danilov, Alexey V.
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2021
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/
https://ncbi.nlm.nih.gov/pubmed/33796237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!